Patient-Derived Extracellular Vesicles Proteins as New Biomarkers in Multiple Myeloma - A Real-World Study

• DOI: 10.3389/fonc.2022.860849
• Publication Date: 2022-06-21T13:33:31Z
• Authors: Bruna Velosa Ferr...; Emilie Arnault Ca...; Carolina Pestana; Filipa Barahona; Joana Caetano; Raquel Lopes; Paulo Lúcio; Manuel Neves; Hans Christian Beck; Ana Sofia Carvalho; Rune Matthiesen; Bruno Costa-Silva; Cristina João
• Keywords: Proteome; Extracellular vesicles; Myeloma protein

Multiple myeloma (MM) is a hematological malignancy of clonal antibody-secreting plasma cells (PCs). MM diagnosis and risk stratification rely on bone marrow (BM) biopsy, an invasive procedure prone to sample bias. Liquid biopsies, such as extracellular vesicles (EV) in peripheral blood (PB), hold promise new minimally tools. Real-world studies analyzing patient-derived EV proteome are rare. Here, we characterized small protein content from PB BM samples cohort 102 monoclonal gammopathies patients routinely followed the clinic 223 111 were included. We investigated whether particle concentration could predict patient prognosis. found that high protein/particle ratio, or cargo >0.6 µg/108 particles, related poorer survival immune dysfunction. These results supported at level by mass spectrometry. report set EV-proteins (PDIA3, C4BPA, BTN1A1, TNFSF13) with biomarker potential for outcomes. The proteomic similarity between matched pairs supports use circulating counterpart proteome. Overall, outcomes, survival, dysfunction, possibly treatment response.